15 Jul 2021, Eastern Time (ET)
Genuity Science is bringing together a distinguished panel of experts from academia, research and industry to discuss opportunities and advancements in developing better treatments for systemic lupus erythematosus (SLE). SLE is a chronic and relapsing autoimmune disease characterized by a break-down of self-tolerance that leads to tissue inflammation and multiorgan damage.
SLE is extremely heterogeneous in nature, with the signs and symptoms varying from person to person, which can often lead to delays in diagnosis. The treatment landscape for SLE today is comprised primarily of non-specific therapies such as antimalarials, corticosteroids, immunosuppressants and biologics. These treatments are often unsuccessful in treating the patients — particularly those with a more severe form of the disease — and longer term, these treatments can be associated with several side effects including infections, hepatotoxicity, osteoporosis and more. Episodic flares of symptoms frequently necessitate changes in medications or dosages, further complicating management of the disease.
This webinar includes an examination of why researching lupus is so complex and the fundamental challenges of SLE research. Speakers also explore where the field has advanced and where opportunities to deepen understanding still exist in order to accelerate the development of new drugs for this underserved group of patients.
Richard Furie, M.D. Chief, Division of Rheumatology, Northwell Health; Professor of Medicine, Zucker School of Medicine at Hofstra/Northwell
Michelle Petri, M.D. Professor of Medicine, Johns Hopkins University School of Medicine
Keith Elkon, M.D. Professor of Medicine and Immunology, Co-Director of the Center for Innate Immunity and Immune Diseases, University of Washington
Professor Ian N. Bruce, M.D., FRCP Director, NIHR Manchester Biomedical Research Centre, University of Manchester, United Kingdom
John Dowling Sales VP, Genuity Science (Moderator)